×
QQQ   290.08 (+1.09%)
AAPL   143.57 (+1.42%)
MSFT   267.17 (+1.64%)
META   170.29 (+1.25%)
GOOGL   2,293.41 (+1.24%)
AMZN   115.14 (+1.44%)
TSLA   697.89 (-0.19%)
NVDA   152.78 (+2.10%)
NIO   20.79 (-6.27%)
BABA   119.15 (-0.82%)
AMD   76.02 (+1.09%)
MU   57.88 (+2.03%)
CGC   2.68 (-1.11%)
T   21.17 (+0.09%)
GE   61.94 (-0.15%)
F   11.17 (-0.27%)
DIS   96.70 (-0.49%)
AMC   12.59 (-1.49%)
PFE   52.44 (+1.55%)
PYPL   73.78 (-0.83%)
NFLX   185.16 (-0.39%)
QQQ   290.08 (+1.09%)
AAPL   143.57 (+1.42%)
MSFT   267.17 (+1.64%)
META   170.29 (+1.25%)
GOOGL   2,293.41 (+1.24%)
AMZN   115.14 (+1.44%)
TSLA   697.89 (-0.19%)
NVDA   152.78 (+2.10%)
NIO   20.79 (-6.27%)
BABA   119.15 (-0.82%)
AMD   76.02 (+1.09%)
MU   57.88 (+2.03%)
CGC   2.68 (-1.11%)
T   21.17 (+0.09%)
GE   61.94 (-0.15%)
F   11.17 (-0.27%)
DIS   96.70 (-0.49%)
AMC   12.59 (-1.49%)
PFE   52.44 (+1.55%)
PYPL   73.78 (-0.83%)
NFLX   185.16 (-0.39%)
QQQ   290.08 (+1.09%)
AAPL   143.57 (+1.42%)
MSFT   267.17 (+1.64%)
META   170.29 (+1.25%)
GOOGL   2,293.41 (+1.24%)
AMZN   115.14 (+1.44%)
TSLA   697.89 (-0.19%)
NVDA   152.78 (+2.10%)
NIO   20.79 (-6.27%)
BABA   119.15 (-0.82%)
AMD   76.02 (+1.09%)
MU   57.88 (+2.03%)
CGC   2.68 (-1.11%)
T   21.17 (+0.09%)
GE   61.94 (-0.15%)
F   11.17 (-0.27%)
DIS   96.70 (-0.49%)
AMC   12.59 (-1.49%)
PFE   52.44 (+1.55%)
PYPL   73.78 (-0.83%)
NFLX   185.16 (-0.39%)
QQQ   290.08 (+1.09%)
AAPL   143.57 (+1.42%)
MSFT   267.17 (+1.64%)
META   170.29 (+1.25%)
GOOGL   2,293.41 (+1.24%)
AMZN   115.14 (+1.44%)
TSLA   697.89 (-0.19%)
NVDA   152.78 (+2.10%)
NIO   20.79 (-6.27%)
BABA   119.15 (-0.82%)
AMD   76.02 (+1.09%)
MU   57.88 (+2.03%)
CGC   2.68 (-1.11%)
T   21.17 (+0.09%)
GE   61.94 (-0.15%)
F   11.17 (-0.27%)
DIS   96.70 (-0.49%)
AMC   12.59 (-1.49%)
PFE   52.44 (+1.55%)
PYPL   73.78 (-0.83%)
NFLX   185.16 (-0.39%)
NASDAQ:BPTH

Bio-Path Stock Forecast, Price & News

$4.17
+0.05 (+1.21%)
(As of 07/6/2022 02:17 PM ET)
Add
Compare
Today's Range
$4.17
$4.17
50-Day Range
$2.84
$4.12
52-Week Range
$2.68
$8.62
Volume
10 shs
Average Volume
44,638 shs
Market Capitalization
$29.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Bio-Path MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
118.4% Upside
$9.00 Price Target
Short Interest
Bearish
5.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Bio-Path in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.89) to ($1.60) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.54 out of 5 stars

Medical Sector

970th out of 1,426 stocks

Pharmaceutical Preparations Industry

478th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

Bio-Path logo

About Bio-Path (NASDAQ:BPTH) Stock

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

BPTH Stock News Headlines

Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com
StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)
Biotechnology's Path To Web3 - Forbes
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPTH
Fax
N/A
Employees
10
Year Founded
N/A

Company Calendar

Last Earnings
5/16/2022
Today
7/06/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+115.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-10,440,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.56 per share

Miscellaneous

Free Float
6,997,000
Market Cap
$29.86 million
Optionable
Not Optionable
Beta
1.62














Bio-Path Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bio-Path stock.
View analyst ratings for Bio-Path
or view top-rated stocks.

What is Bio-Path's stock price forecast for 2022?

1 equities research analysts have issued 1 year price targets for Bio-Path's stock. Their BPTH stock forecasts range from $9.00 to $9.00. On average, they predict Bio-Path's stock price to reach $9.00 in the next year. This suggests a possible upside of 115.8% from the stock's current price.
View analysts' price targets for Bio-Path
or view top-rated stocks among Wall Street analysts.

How has Bio-Path's stock performed in 2022?

Bio-Path's stock was trading at $3.77 at the beginning of 2022. Since then, BPTH shares have increased by 10.6% and is now trading at $4.17.
View the best growth stocks for 2022 here
.

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Bio-Path
.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its earnings results on Monday, May, 16th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.01. During the same quarter last year, the firm posted ($0.43) earnings per share.
View Bio-Path's earnings history
.

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Bio-Path's stock reverse split on the morning of Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

Who are Bio-Path's key executives?

Bio-Path's management team includes the following people:
  • Mr. Peter H. Nielsen MBA, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 73, Pay $680.18k)
  • Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 66, Pay $68.47k)
  • Mr. Anthony Price, Sr. VP of Fin., Accounting & Admin.
  • Dr. Ana Tari Ashizawa Ph.D., MBA, Sr. VP of Research, Devel. & Clinical Design
  • Dr. Alan MacKenzie Ph.D., Consultant
  • Dr. Thomas A. Walker Ph.D., Consultant
  • Dr. Jeffery Lancet M.D., Consultant
  • Ms. Victoria Lake Rac, Regulatory Consultant

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), (CGC), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $4.17.

How much money does Bio-Path make?

Bio-Path (NASDAQ:BPTH) has a market capitalization of $29.86 million. The company earns $-10,440,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.

How many employees does Bio-Path have?

Bio-Path employs 10 workers across the globe.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The official website for Bio-Path is www.biopathholdings.com. The company can be reached via phone at (832) 742-1357 or via email at will@sternir.com.

This page (NASDAQ:BPTH) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.